Clinical trial · Observational
The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
The Role of 18F-FDG & 68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastatic
NCT06597526CI-TRIAL-00080583recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate the value of 18F-FDG\&68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Peritoneal Metastasis | Gastric Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- gastric cancer patients with peritoneal metastasis
- description
- Initial diagnosis of gastric cancer with peritoneal metastases, excluding other distant metastases
Primary outcomes (3)
- measure
- Target-to-background ratio(TBR)
- timeFrame
- Baseline, preoperative assessment and time of postoperative recurrence assessment
- description
- 68Ga-FAPI and 18F-FDG uptake ratio of primary gastric lesions, peritoneal lesions and recurrent metastatic lesions to mediastinum and liver blood pool on PET/CT images.
- measure
- Standardized uptake value(SUV)
- timeFrame
- Baseline, preoperative assessment and time of postoperative recurrence assessment
- description
- SUV of 68Ga-FAPI and 18F-FDG uptake on PET/CT images for primary gastric lesions, peritoneal lesions and recurrent metastatic lesions
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed gastric adenocarcinoma with no history of resection of primary or metastatic lesions 2. Peritoneal metastases of gastric cancer requiring laparoscopy for definitive diagnosis without gastric outflow tract obstruction and intestinal obstruction 3. Patients voluntarily enrolled in this study by signing an informed consent form 4. Age ≥ 18 years 5. Eastern Cooperative Oncology Group (ECOG) score ≤ 2, 6. Expected life expectancy ≥ 3 months 7. Adequate organ and bone marrow function 8. Willingness to adhere to the study protocol and follow-up programme Exclusion Criteria: 1. Signs of distant metastases other than peritoneal metastases at enrolment 2. Pregnant or breastfeeding women. 3. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix 4. Severe mental disease, uncontrolled epilepsy, or central nervous system disease
References
Publications (0)
Data not yet available
No reference posted for this study.